Longterm Effects of Intraarticular Hyaluronan vs Corticosteroid in Osteoarthritis of the Hip: A Randomized Controlled Trial

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-022106-40-NL

Enrollment

300

Registered

2010-08-30

Start date

2014-06-10

Completion date

Unknown

Last updated

2014-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coxarthrosis MedDRA version: 12.1 Level: LLT Classification code 10048793 Term: Coxarthrosis

Interventions

Trade Name: Depomedrol Product Name: Depomedrol Product Code: RVG 00605 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: METHYLPREDNISOLONE ACEPONATE CAS Number: 86401-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: above 18 years-old symptomatic coxarthrosis signed informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: bad health ipsilateral gonarthritis clinical significant neurovascular disease former surgical procedures of the hip osteonecrosis, osteomyelitis of the hip allergy to components of Fermatron, Depomedrol or lidocaine

Design outcomes

Primary

Measure	Time frame
Main Objective: The primary purpose of the study is to determine the difference in pain reduction and functional recovery between the researchgroups.;Secondary Objective: 1 and 2 years after randomization, an assessment carried out between, this is calculated the percentage of patients in the study received a THP. In addition, radiological progression during outpatient visits evaluated by X-ray (every half year) review. ;Primary end point(s): The primary purpose of the study is to determine the difference in pain reduction and functional recovery between the researchgroups.	—

Measure

Time frame

Main Objective: The primary purpose of the study is to determine the difference in pain reduction and functional recovery between the researchgroups.;Secondary Objective: 1 and 2 years after randomization, an assessment carried out between, this is calculated the percentage of patients in the study received a THP. In addition, radiological progression during outpatient visits evaluated by X-ray (every half year) review. ;Primary end point(s): The primary purpose of the study is to determine the difference in pain reduction and functional recovery between the researchgroups.

—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026